Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
No Need to Alter TKI Treatment in These Patients
Am J Hematol; ePub 2017 Oct 13; Alhuraiji, et al
In people with chronic myeloid leukemia (CML) being treated with tyrosine kinase inhibitors (TKIs), having additional cytogenetic abnormalities (ACA) at diagnosis does not confer worse 5-year prognosis, according to an analysis involving 603 individuals. Investigators looked at outcomes in participants from prospective studies who had chronic phase CML with or without ACA at diagnosis treated with frontline TKIs. Among the results:
- 5% of patients had ACA.
- Patients without ACA had a significantly higher rate of complete cytogenetic response (CCyR) at 6 months.
- Cumulative CCyR and major molecular response rates were not different between those with and without ACA.
- At 5 years, ACA at diagnosis did not significantly impact transformation-free, failure-free, event-free, or overall survival rates.
The authors noted that treatment approach should not be altered in patients who have ACA at diagnosis.
Alhuraiji A, Kantarjian H, Boddu P, et al. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. [Published online ahead of print October 13, 2017]. Am J Hematol. doi:10.1002/ajh.24943.
